Gilead Sciences Management

Management criteria checks 3/4

Gilead Sciences' CEO is Dan O'Day, appointed in Mar 2019, has a tenure of 4.5 years. total yearly compensation is $21.62M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth €27.17M. The average tenure of the management team and the board of directors is 3.6 years and 5.7 years respectively.

Key information

Dan O'Day

Chief executive officer

US$21.6m

Total compensation

CEO salary percentage	7.8%
CEO tenure	4.5yrs
CEO ownership	0.03%
Management average tenure	3.6yrs
Board average tenure	5.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan O'Day's remuneration changed compared to Gilead Sciences's earnings?
Date	Total Comp.	Salary	Company Earnings
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Compensation vs Market: Dan's total compensation ($USD21.62M) is above average for companies of similar size in the German market ($USD4.72M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan O'Day (59 yo)

4.5yrs

Tenure

US$21,621,253

Compensation

Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019. He served as Member of Supervisory Board at Galapagos NV since October 22,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% $ 27.2m
Andrew Dickinson	Executive VP & CFO	3.8yrs	US$8.40m	0.0088% $ 7.7m
Deborah Telman	Executive VP of Corporate Affairs	1.1yrs	US$4.82m	0.00052% $ 458.9k
Johanna Mercier	Chief Commercial Officer	4.2yrs	US$9.24m	0.0072% $ 6.3m
Merdad Parsey	Chief Medical Officer	3.8yrs	US$9.04m	0.0056% $ 5.0m
Sandra Patterson	Senior VP	less than a year	no data	0.0024% $ 2.1m
Jacquie Ross	Vice President of Investor Relations	2.7yrs	no data	no data
Jyoti Mehra	Executive Vice President of Human Resources	4.1yrs	no data	no data
Michael Quigley	Senior Vice President of Research Biology	3.6yrs	no data	no data
Linda Higgins	Senior Vice President of Research	3.6yrs	no data	no data
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	no data	no data
Flavius Martin	Executive Vice President of Research	2.4yrs	no data	no data

3.6yrs

Average Tenure

58yo

Average Age

Experienced Management: GIS's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% $ 27.2m
Anthony Welters	Independent Director	2.9yrs	US$429.93k	0.00064% $ 564.8k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	no data
Jacqueline Barton	Independent Director	5.7yrs	US$414.88k	0.0018% $ 1.6m
Eugene Schiff	Member of the Scientific Advisory Board	no data	no data	no data
Robert Schooley	Member of the Scientific Advisory Board	no data	no data	no data
John Mellors	Member of the Scientific Advisory Board	no data	no data	no data
Francis Chisari	Member of the Scientific Advisory Board	no data	no data	no data
Paul Klotman	Member of the Scientific Advisory Board	no data	no data	no data
Kevin Lofton	Lead Independent Director	14.2yrs	US$489.93k	0.0074% $ 6.6m
Kelly Kramer	Independent Director	7.1yrs	US$434.93k	0.00011% $ 97.1k
Joel Huff	Chairperson of Scientific Advisory Board	no data	no data	no data

5.7yrs

Average Tenure

68yo

Average Age

Experienced Board: GIS's board of directors are considered experienced (5.7 years average tenure).

Gilead Sciences Management

Management criteria checks 3/4

Key information

Recent management updates

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. Announces Executive Changes

Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel

Gilead Sciences, Inc. Announces Executive Changes

Recent updates

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

New minor risk - Financial position

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.84 (vs US$0.91 in 2Q 2022)

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care At Asco 2023

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. (NasdaqGS:GILD) acquired Xinthera, Inc.

First quarter 2023 earnings released: EPS: US$0.81 (vs US$0.015 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 3.7% yield

Gilead Sciences, Inc. Announces Updated Positive Results from Three Cohorts of the Phase 2 Trophy-U-01 Study of Trodelvy®

Full year 2022 earnings released: EPS: US$3.66 (vs US$4.96 in FY 2021)

Gilead Sciences, Inc. Announces U.S. FDA Approves Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. to Report Q4, 2022 Results on Feb 02, 2023

Gilead Sciences, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Trodelvy(R) (Sacituzumab Govitecan-Hziy) for Pre-Treated Hr+/Her2- Metastatic Breast Cancer

Gilead Sciences, Inc.'s Sunlenca(R) (Lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

Kite's Tecartus Car T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New Data From Post-Hoc Analysis from Phase 3 TROPiCS-02 Study

Gilead Sciences, Inc Announces U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis At the Liver Meeting® 2022

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Third quarter 2022 earnings released: EPS: US$1.43 (vs US$2.06 in 3Q 2021)

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Gilead Sciences, Inc. Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living with HIV with A Range of Comorbidities

Gilead Presents Real-World and Long-Term Data from HIV Research Programs At HIV Glasgow 2022

Gilead Sciences, Inc. to Report Q3, 2022 Results on Oct 27, 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Hiv-Positive Consumer Joins Lawsuit Against Gilead Sciences, Inc. over Price Gouging

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of MiroBio Ltd.

Gilead Sciences, Inc. Announces Committee for Medicinal Products for Human Use of European Medicines Agency Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for Treatment of Pediatric Patients with COVID-19

Gilead Sciences, Inc. Announces the Positive Overall Survival Results from the Phase 3 TROPiCS-02 Study Evaluating Trodelvy

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy Regardless of Their HER2 Status

Gilead Sciences, Inc. Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

Gilead Sciences, Inc. Announces Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/Her2- Metastatic Breast Cancer Patients in the Tropics-02 Study

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire MiroBio Ltd from SR One Capital Management, LP, Samsara BioCapital LLC, Oxford Science Enterprises, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and Advent Life Sciences LLP for approximately $410 million.

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$1.21 in 2Q 2021)

Gilead Sciences, Inc. Declares Quarterly Cash Dividend for the Third Quarter of 2022, Payable on September 29, 2022

Gilead Sciences, Inc. Announces Executive Changes

Gilead Sciences, Inc. Announces Results Reinforcing Biktarvy

Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Gilead Sciences, Inc.'s Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients with Covid-19

Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel

GlaxoSmithKline plc (LSE:GSK) completed the acquisition of Sierra Oncology, Inc. (NasdaqGM:SRRA) from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opinion for People with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces Week 48 Results from the Pivotal Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepcludex® (Bulevirtide) for the Treatment of Chronic Hepatitis Delta Virus (Hdv) Infection

Gilead Sciences New Data Highlights People Living with Hiv Who Are Virally Suppressed Experience Similar Health-Related Quality of Life as General Population

Upcoming dividend of US$0.73 per share

Final Data from Phase 3 Ascent Study Demonstrates Trodelvy Extends Overall Survival over Chemotherapy in Second-Line Metastatic TNBC

Gilead Sciences, Inc. Announces Positive Results from the Primary Analysis of the Phase 3 TROPiCS-02 Study of Trodelvy®

Gilead Sciences, Inc. Announces Executive Changes

U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

First quarter 2022 earnings released: EPS: US$0.015 (vs US$1.38 in 1Q 2021)